Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726, HR 3200, HR 3495 and H.R. 1548).
Duration: November 1, 2007
to
May 1, 2010
General Issues: Health Issues , Pharmacy , Medicare/Medicaid , Insurance
Spending: about $420,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate,, U.S. Senate, Office of Management & Budget (OMB), White House Office, Health & Human Services - Dept of (HHS), Congressional Budget Office (CBO), Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
KATHERINE HAYES HEALTH COUNSEL, US SENATOR EVAN BAYH
HEALTH COUNSEL, US SENATOR EVAN B AYH
Health Counsel, U.S. Senator Evan Bayh
Christopher Jennings n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2010
Jennings Policy Strategies terminated an engagement in which they represented GENERIC PHARMACEUTICAL ASSOCIATION on June 1, 2010.
Original Filing: 300279645.xml
1st Quarter, 2010
In Q1, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $60,000. The report was filed on April 20, 2010.
Original Filing: 300274095.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726, HR 3200, HR 3495 and H.R. 1548).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $60,000. The report was filed on Jan. 20, 2010.
Original Filing: 300248145.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Average Manufacturers Price/AMP including H.R. 6331
Any matters relating to access to generic drugs
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $60,000. The report was filed on Oct. 20, 2009.
Original Filing: 300221505.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Average Manufacturers Price/AMP including H.R. 6331
Any matters relating to access to generic drugs
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $40,000. The report was filed on July 20, 2009.
Original Filing: 300193413.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Average Manufacturers Price/AMP including H.R. 6331
Any matters relating to access to generic drugs
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
Jennings Policy Strategies amended a lobbying report for representation of GENERIC PHARMACEUTICAL ASSOCIATION in Q12009 on April 21, 2009.
Original Filing: 300166081.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Average Manufacturers Price/AMP including H.R. 6331
Any matters relating to access to generic drugs
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $40,000. The report was filed on Jan. 21, 2009.
Original Filing: 300134156.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).
Food and Drug Administration Amendents Act of 2007 (H.R. 3580)
Counterfeit Drugs/Import safety/Pedigree
Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296)
Prescription drug importation/re-importation
Average Manufacturers Price/AMP
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).
Food and Drug Administration Amendents Act of 2007 (H.R. 3580)Counterfeit Drugs/Import safety/Pedigree
Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296)
Prescription drug importation/re-importation
Average Manufacturers Price/AMP
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Average Manufacturers Price/AMP including H.R. 6331
Any matters relating to access to generic drugs
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $40,000. The report was filed on Oct. 20, 2008.
Original Filing: 300104612.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).
Food and Drug Administration Amendents Act of 2007 (H.R. 3580)
Citizens Petitions, including but not limited to S. 25 and S. 1080Counterfeit Drugs/Import safety/Pedigree
Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296)
Prescription drug importation/re-importation
Average Manufacturers Price/AMP
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Average Manufacturers Price/AMP including H.R. 6331
Any matters relating to access to generic drugs
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $40,000. The report was filed on July 21, 2008.
Original Filing: 300077088.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace, including Medicaid rebates.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $40,000. The report was filed on April 20, 2009.
Original Filing: 300165548.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Average Manufacturers Price/AMP including H.R. 6331
Any matters relating to access to generic drugs
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $40,000. The report was filed on April 21, 2008.
Original Filing: 300054931.xml
Lobbying Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including H.R. 1038, S. 623, H.R. 5629).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
0th Quarter, 2007
In MM, Jennings Policy Strategies lobbied for GENERIC PHARMACEUTICAL ASSOCIATION , earning $80,000. The report was filed on Aug. 6, 2007.
Original Filing: 200046232.xml
Lobbying Issues
-Advocated for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including H.R. 1083 and S. 623)
Type of Issue
Health Issues
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...